We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck (MRK) Stock Moves -0.24%: What You Should Know
Read MoreHide Full Article
Merck (MRK - Free Report) closed the most recent trading day at $86.39, moving -0.24% from the previous trading session. The stock exceeded the S&P 500, which registered a loss of 4.84% for the day. Meanwhile, the Dow lost 3.98%, and the Nasdaq, a tech-heavy index, lost 5.97%.
The the stock of pharmaceutical company has fallen by 7.07% in the past month, lagging the Medical sector's loss of 4.6% and the S&P 500's loss of 4.7%.
Investors will be eagerly watching for the performance of Merck in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on April 24, 2025. The company is predicted to post an EPS of $2.16, indicating a 4.35% growth compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $15.65 billion, down 0.77% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $9 per share and a revenue of $65.25 billion, indicating changes of +17.65% and +1.69%, respectively, from the former year.
Any recent changes to analyst estimates for Merck should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.09% lower. Merck presently features a Zacks Rank of #3 (Hold).
Investors should also note Merck's current valuation metrics, including its Forward P/E ratio of 9.62. This expresses a discount compared to the average Forward P/E of 13.53 of its industry.
Investors should also note that MRK has a PEG ratio of 0.76 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 1.33.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 69, this industry ranks in the top 28% of all industries, numbering over 250.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Merck (MRK) Stock Moves -0.24%: What You Should Know
Merck (MRK - Free Report) closed the most recent trading day at $86.39, moving -0.24% from the previous trading session. The stock exceeded the S&P 500, which registered a loss of 4.84% for the day. Meanwhile, the Dow lost 3.98%, and the Nasdaq, a tech-heavy index, lost 5.97%.
The the stock of pharmaceutical company has fallen by 7.07% in the past month, lagging the Medical sector's loss of 4.6% and the S&P 500's loss of 4.7%.
Investors will be eagerly watching for the performance of Merck in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on April 24, 2025. The company is predicted to post an EPS of $2.16, indicating a 4.35% growth compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $15.65 billion, down 0.77% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $9 per share and a revenue of $65.25 billion, indicating changes of +17.65% and +1.69%, respectively, from the former year.
Any recent changes to analyst estimates for Merck should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.09% lower. Merck presently features a Zacks Rank of #3 (Hold).
Investors should also note Merck's current valuation metrics, including its Forward P/E ratio of 9.62. This expresses a discount compared to the average Forward P/E of 13.53 of its industry.
Investors should also note that MRK has a PEG ratio of 0.76 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 1.33.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 69, this industry ranks in the top 28% of all industries, numbering over 250.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.